As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
BUSINESS
Takeda’s 9-Month Sales Skid 3.6% on Dips in Rare Diseases, Neuroscience
Takeda Pharmaceutical said on February 4 that its nine-month revenue for April-December edged down 3.6% due to sluggish product sales in its rare disease and neuroscience franchises, but its profit more than doubled in a rebound from a year ago,…
To read the full story
Related Article
- Takeda’s Q1 Sales Rise on Diabetes Divestiture; Plant Re-Inspection Results Expected Late October
August 2, 2021
- Takeda’s FY2020 Profits Jump on Non-Core Divestitures, Post-Shire Cost Synergies
May 12, 2021
- Takeda Done with Majority of Non-Core Asset Divestitures with US$10 Billion Target Achieved: CEO
October 30, 2020
- Takeda’s Half-Year Operating Profit Nearly Doubles on Drop in Costs, Shire Synergies
October 30, 2020
- Takeda Ups Full-Year Profit Guidance after EU Clears Obligation to Divest SHP647
August 3, 2020
BUSINESS
- Nippon Shinyaku Bags US License Option for AB2 Bio’s Tadekinig Alfa
January 28, 2025
- Leqembi’s Monthly IV Maintenance Dosing Approved in US
January 28, 2025
- Astellas Slashes Full-Year Profit Forecasts on Impairment Loss of Izervay and More
January 27, 2025
- Rakuten Medical Launches Global PIII Trial of Photoimmunotherapy/Keytruda Combo
January 27, 2025
- Lenvima/Keytruda Combo Misses OS Goal in 1st Line GI Cancer Trial
January 27, 2025
A total of 43 innovative new medicines are anticipated to be approved or listed in Japan this year, according to a survey by Jiho. At the center of attention are some highly innovative, but probably ultra-expensive, gene therapies, as well…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…